Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/29/2019
Start Date:June 9, 2017
End Date:December 28, 2025
Contact:Toll Free Number
Email:Trialsites@merck.com
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475)
in the adjuvant treatment of adult participants who have undergone nephrectomy and have
intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma
(RCC) with clear cell component.

The primary study hypothesis is that pembrolizumab is superior to placebo with respect to
Disease-free Survival (DFS) as assessed by the Investigator in male and female participants
with intermediate-high risk, high risk and M1 NED RCC.

Participants will be assigned to receive study treatment until disease recurrence,
unacceptable adverse events (AEs), intercurrent illness that prevents further administration
of treatment, Investigator's decision to withdraw the participant, noncompliance with study
treatment or procedural requirements, administrative reasons requiring cessation of
treatment, or until the participant has received 17 cycles of study treatment (approximately
1 year). Each cycle is 3 weeks long.

Inclusion Criteria:

- Has histologically confirmed diagnosis of RCC with clear cell component with or
without sarcomatoid features.

- Female participants of childbearing potential must be willing to use an adequate
method of contraception, for the course of the study through 120 days after the last
dose of study treatment.

- Male participants of childbearing potential must agree to use an adequate method of
contraception, starting with the first dose of study treatment through 120 days after
the last dose of study treatment.

- Has intermediate-high risk, high risk, or M1 NED RCC as defined by the following
pathological tumor-node-metastasis and Fuhrman grading status:

1. Intermediate-high risk RCC: pT2, Grade 4 or sarcomatoid, N0, M0; pT3, Any Grade,
N0, M0

2. High risk RCC: pT4, Any Grade N0, M0; pT, Any stage, Any Grade, N+, M0

3. M1 NED RCC participants who present not only with the primary kidney tumor but
also solid, isolated, soft tissue metastases that can be completely resected at
one of the following: the time of nephrectomy (synchronous) or, ≤1 year from
nephrectomy (metachronous).

- Has received no prior systemic therapy for advanced RCC.

- Has undergone a partial nephroprotective or radical complete nephrectomy (and complete
resection of solid, isolated, soft tissue metastatic lesion(s) in M1 NED participants)
with negative surgical margins.

- Must have undergone a nephrectomy and/or metastasectomy ≥28 days prior to signing
informed consent and ≤12 weeks prior to randomization.

- Must be tumor-free as assessed by the Investigator and validated by either computed
tomography (CT) or magnetic resonance imaging (MRI) scan of the brain and chest,
abdomen, and pelvis and a bone scan ≤28 days from randomization.

- Must have provided adequate tissue per the following: Nephrectomy only: tissue from
nephrectomy (required); Synchronous M1 NED: tissue from nephrectomy (required) AND,
metastasectomy tissue (if available); Metachronous M1 NED: tissue from metastasectomy
(required) AND, nephrectomy tissue (if available).

- Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or
1.

- Has adequate organ function.

Exclusion Criteria:

- Has had major surgery, other than nephrectomy and/or resection of pre-existing
metastases for M1 NED participants, within 12 weeks prior to randomization.

- Has received prior radiotherapy for RCC.

- Has pre-existing brain or bone metastatic lesions.

- Has residual thrombus post nephrectomy in the vena renalis or vena cava.

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior the first dose of study treatment.

- Has an active autoimmune disease that has required systemic treatment in past 2 years
(i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive
drugs). Replacement therapy is allowed.

- Has a known additional malignancy that is progressing or required active treatment ≤3
years ago. Exceptions include early-stage cancers (carcinoma in situ or Stage 1)
treated with curative intent, basal cell carcinoma of the skin, squamous cell
carcinoma of the skin, in situ cervical cancer, in situ prostate cancer, or in situ
breast cancer that has undergone potentially curative therapy.

- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis.

- Has an active infection requiring systemic therapy.

- Has a history of, or is currently on, dialysis.

- Has a known history of human immunodeficiency virus (HIV) infection.

- Has known active hepatitis B or hepatitis C virus infection.

- Has a known history of active tuberculosis (Bacillus tuberculosis).

- Has had a prior solid organ transplant.

- Has severe hypersensitivity (≥ Grade 3) to pembrolizumab and/or any of its excipients.

- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the Screening visit through 120 days
after the last dose of study treatment.

- Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1),
anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent
directed to another co-inhibitory T-cell receptor (i.e., cytotoxic
T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137 [tumor necrosis factor
receptor superfamily member 9 (TNFRSF9)]) or has previously participated in a Merck
pembrolizumab (MK-3475) clinical trial.

- Has received prior anticancer therapy, monoclonal antibody, chemotherapy, or an
investigational agent or device within 4 weeks or 5 half-lives (whichever is longer)
before first dose of study treatment or not recovered (i.e., must be ≤ Grade 1 or at
Baseline) from AEs due to previously administered agents.

- Has received a live vaccine within 30 days prior to the first dose of study treatment.

- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment.
We found this trial at
61
sites
New Orleans, Louisiana 70112
Phone: 504-702-5171
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Phone: 505-925-0478
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Phone: 617-632-9245
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Phone: 718-405-8405
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Phone: 919-681-9822
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Phone: 605-322-3018
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Ames, Iowa 50010
Phone: 515-239-2621
McFarland Clinic, PC It has been over 65 years since the founders of McFarland Clinic...
?
mi
from
Ames, IA
Click here to add this to my saved trials
500 S State St
Ann Arbor, Michigan 48109
(734) 764-1817
Phone: 734-232-0753
University of Michigan The University of Michigan was founded in 1817 as one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Aurora, Colorado 80012
Phone: 713-245-0474
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Austin, Texas 78731
Phone: 713-254-0474
?
mi
from
Austin, TX
Click here to add this to my saved trials
Baltimore, Maryland 21237
Phone: 443-777-7364
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Billings, Montana 59102
Phone: 406-238-6290
?
mi
from
Billings, MT
Click here to add this to my saved trials
Boca Raton, Florida 33486
Phone: 561-955-5630
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
450 Brookline Avenue
Boston, Massachusetts 02215
Phone: 617-632-5261
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bradenton, Florida 34205
Phone: 941-792-0340
?
mi
from
Bradenton, FL
Click here to add this to my saved trials
Charleston, South Carolina 29403
Phone: 713-254-0474
?
mi
from
Charleston, SC
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Phone: 843-792-2306
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
5053 Wooster Rd
Cincinnati, Ohio 45226
(513) 751-2273
Phone: 713-245-0474
Oncology Hematology Care Our more than 60 physicians and advanced practice providers throughout neighborhood offices...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dallas, Texas 75246
Phone: 713-245-0474
?
mi
from
Dallas, TX
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Phone: 410-502-4658
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Denton, Texas 76210
Phone: 281-863-6712
?
mi
from
Denton, TX
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Phone: 313-916-1784
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Detroit, Michigan 48201
Phone: 313-576-9703
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Easton, Pennsylvania 18045
Phone: 484-503-4157
?
mi
from
Easton, PA
Click here to add this to my saved trials
Edina, Minnesota 55435
Phone: 612-672-5233
?
mi
from
Edina, MN
Click here to add this to my saved trials
1717 13th St
Everett, Washington 98201
(425) 297-5500
Phone: 425-261-3544
Providence Regional Cancer Partnership Founded in 2007, the Providence Regional Cancer Partnership is the result...
?
mi
from
Everett, WA
Click here to add this to my saved trials
Houston, Texas 77024
Phone: 713-245-0474
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77030
Phone: 832-325-7702
?
mi
from
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
Phone: 319-356-4568
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
9280 W. Sunset Road Suite 100
Las Vegas, Nevada 89148
702.952.1251
Phone: 702-952-1251
Comprehensive Cancer Centers of Nevada Comprehensive Cancer Centers of Nevada (CCCN) is the award-winning multidisciplinary...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Phone: 323-865-3956
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
600 Highland Ave.
Madison, Wisconsin 53792
(608) 263-6400
Phone: 608-263-7107
University of Wisconsin Carbone Cancer Center UW Carbone Cancer Center holds the unique distinction of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Marietta, Georgia 30060
Phone: 770-281-5156
?
mi
from
Marietta, GA
Click here to add this to my saved trials
Minneapolis, Minnesota 55404
Phone: 713-245-0474
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Nashville, Tennessee 37209
Phone: 615-250-9240
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Phone: 732-235-6048
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Niles, Illinois 60714
Phone: 218-863-6685
?
mi
from
Niles, IL
Click here to add this to my saved trials
5900 Lake Wright Dr
Norfolk, Virginia 23502
(757) 466-8683
Phone: 713-245-0474
Virginia Oncology Associates Virginia Oncology Associates is an oncology and hematology practice of physicians, specializing...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Omaha, Nebraska 68114
Phone: 402-334-4773
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Paris, Texas 75460
Phone: 281-863-6712
?
mi
from
Paris, TX
Click here to add this to my saved trials
Pensacola, Florida 32503
Phone: 713-245-0474
?
mi
from
Pensacola, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Phone: 215-662-7383
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona 85016
Phone: 602-277-4868
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rockville, Maryland 20850
Phone: 713-245-0474
?
mi
from
Rockville, MD
Click here to add this to my saved trials
860 Boulevard Oroño
Rosario, Santa Fe 2000
Phone: +5493416149812
?
mi
from
Rosario,
Click here to add this to my saved trials
Royal Oak, Michigan 48073
Phone: 248-957-8940
?
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Saint Louis Park, Minnesota 55426
Phone: 952-993-6705
?
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Salt Lake City, Utah 84106
Phone: 801-281-6864
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
San Antonio, Texas 78229
Phone: 210-450-5798
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
2219 Bath Street
Santa Barbara, California 93105
Phone: 713-245-0474
?
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
825 Eastlake Avenue East
Seattle, Washington 98109
Phone: 206-288-7476
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Spokane, Washington 99218
Phone: 509-228-1687
?
mi
from
Spokane, WA
Click here to add this to my saved trials
6001 North Mayfair Street
Spokane, Washington 99208
Phone: 509-462-2273
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Stanford, California 94305
Phone: 650-736-1640
?
mi
from
Stanford, CA
Click here to add this to my saved trials
Tacoma, Washington 98405
Phone: 253-428-8725
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
Tualatin, Oregon 97062
Phone: 713-245-0474
?
mi
from
Tualatin, OR
Click here to add this to my saved trials
Tulsa, Oklahoma 74146
Phone: 918-505-3200
?
mi
from
Tulsa, OK
Click here to add this to my saved trials
Tyler, Texas 75702
Phone: 713-245-0474
?
mi
from
Tyler, TX
Click here to add this to my saved trials
Waco, Texas 76712
Phone: 218-863-6685
?
mi
from
Waco, TX
Click here to add this to my saved trials
3800 Reservoir Rd NW
Washington, District of Columbia 20007
(202) 687-7695
Phone: 202-687-1116
Georgetown University Medical Center Georgetown University Medical Center is committed to excellence in research, education...
?
mi
from
Washington,
Click here to add this to my saved trials
2811 Tieton Drive
Yakima, Washington 98902
Phone: 216-863-6685
?
mi
from
Yakima, WA
Click here to add this to my saved trials